SU 5220

Drug Profile

SU 5220

Alternative Names: Neoasterriquinone

Latest Information Update: 29 Feb 2008

Price : $50

At a glance

  • Originator MDS Pharma Services; SUGEN; University of Michigan Medical School
  • Class Indoles; Quinones; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; GRB2 protein inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 18 Jun 2002 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 13 Oct 1999 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top